GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Change In Other Working Capital

CEL-SCI (CEL-SCI) Change In Other Working Capital : $-2.32 Mil (TTM As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Change In Other Working Capital?

CEL-SCI's Change In Other Working Capital for the quarter that ended in Dec. 2023 was $0.00 Mil. It means CEL-SCI's Other Working Capital stayed the same from Sep. 2023 to Dec. 2023 .

CEL-SCI's Change In Other Working Capital for the fiscal year that ended in Sep. 2023 was $-2.32 Mil. It means CEL-SCI's Other Working Capital declined by $2.32 Mil from Sep. 2022 to Sep. 2023 .


CEL-SCI Change In Other Working Capital Historical Data

The historical data trend for CEL-SCI's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Change In Other Working Capital Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.03 -0.24 1.86 -2.32

CEL-SCI Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -2.32 -

CEL-SCI Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CEL-SCI Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (CEL-SCI) Business Description

Industry
Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182